Positive dupixent® (dupilumab) phase 3 results in adults and adolescents with eosinophilic esophagitis published in the new england journal of medicine

Dupixent 300 mg weekly showed significant histological disease remission and improvement in symptoms of the disease compared to placebo improvements were sustained for up to one year in patients aged 12 years and older with eosinophilic esophagitis (eoe) dupixent is the first and only targeted medicine indicated in the u.s. to treat eoe patients aged 12 and older weighing at least 40 kg tarrytown, n.y. and paris , dec. 21, 2022 /prnewswire/ -- regeneron pharmaceuticals, inc. (nasdaq: regn) and sanofi today announced the new england journal of medicine has published results from a positive phase 3 trial showing adults and adolescents treated with dupixent® (dupilumab) 300 mg weekly experienced significant improvements in signs and symptoms of eosinophilic esophagitis (eoe), which were sustained for up to one year.
REGN Ratings Summary
REGN Quant Ranking